share_log

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $51

Benzinga ·  Jul 12 01:16

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $48 to $51.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment